APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oligonucleotide CDMO Market Outlook and Growth Opportunities 2026

Report ID 174201460415 April 2026Not stated

Choose your research edition.

Industry ResearchOligonucleotide CDMO Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide CDMO Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Oligonucleotide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide CDMO Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Oligonucleotide CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oligonucleotide CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oligonucleotide CDMO market include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI and Veliter, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oligonucleotide CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligonucleotide CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligonucleotide CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oligonucleotide CDMO market.

Oligonucleotide CDMO Segment by Company

Agilent

ST Pharm

Bachem

BioSpring

Creative Biogene

Sylentis

Ajinomoto Bio-Pharma

EUROAPI

Veliter

PolyPeptide Group

CordenPharma

Thermofischer

Bio Basic

Genscript

Cytiva

ScinoPharm

CBL

Piramal Pharma

CPC Scientific

Eurogentec

Cambrex

WuXi STA

Oligonucleotide CDMO Segment by Type

APIs and Intermediates

FDF

Oligonucleotide CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Oligonucleotide CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oligonucleotide CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oligonucleotide CDMO key companies, revenue, market share, and recent developments.

3. To split the Oligonucleotide CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oligonucleotide CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oligonucleotide CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Oligonucleotide CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide CDMO industry.

Chapter 3: Detailed analysis of Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oligonucleotide CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oligonucleotide CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oligonucleotide CDMO Industry Trends Table 2. Oligonucleotide CDMO Industry Drivers Table 3. Oligonucleotide CDMO Industry Opportunities and Challenges Table 4. Oligonucleotide CDMO Industry Restraints Table 5. Global Oligonucleotide CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oligonucleotide CDMO Revenue Share by Company (2021-2026) Table 7. Global Oligonucleotide CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oligonucleotide CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Oligonucleotide CDMO Company, Product Type & Application Table 10. Global Oligonucleotide CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oligonucleotide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of APIs and Intermediates Table 15. Significant Companies of FDF Table 16. Global Oligonucleotide CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Oligonucleotide CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Oligonucleotide CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Oligonucleotide CDMO Sales Value Share by Type (2021-2026) Table 20. Global Oligonucleotide CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical and Biotechnology Companies Table 22. Significant Companies of Research Institutes Table 23. Significant Companies of Others Table 24. Global Oligonucleotide CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Oligonucleotide CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Oligonucleotide CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Oligonucleotide CDMO Sales Value Share by Application (2021-2026) Table 28. Global Oligonucleotide CDMO Sales Value Share by Application (2027-2032) Table 29. Global Oligonucleotide CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oligonucleotide CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Oligonucleotide CDMO Sales Value Share by Region (2021-2026) Table 32. Global Oligonucleotide CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Oligonucleotide CDMO Sales Value Share by Region (2027-2032) Table 34. Global Oligonucleotide CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oligonucleotide CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Oligonucleotide CDMO Sales Value Market Share by Country (2021-2026) Table 37. Global Oligonucleotide CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Oligonucleotide CDMO Sales Value Market Share by Country (2027-2032) Table 39. Agilent Company Information Table 40. Agilent Business Overview Table 41. Agilent Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Agilent Oligonucleotide CDMO Product Portfolio Table 43. Agilent Recent Development Table 44. ST Pharm Company Information Table 45. ST Pharm Business Overview Table 46. ST Pharm Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. ST Pharm Oligonucleotide CDMO Product Portfolio Table 48. ST Pharm Recent Development Table 49. Bachem Company Information Table 50. Bachem Business Overview Table 51. Bachem Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bachem Oligonucleotide CDMO Product Portfolio Table 53. Bachem Recent Development Table 54. BioSpring Company Information Table 55. BioSpring Business Overview Table 56. BioSpring Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. BioSpring Oligonucleotide CDMO Product Portfolio Table 58. BioSpring Recent Development Table 59. Creative Biogene Company Information Table 60. Creative Biogene Business Overview Table 61. Creative Biogene Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Creative Biogene Oligonucleotide CDMO Product Portfolio Table 63. Creative Biogene Recent Development Table 64. Sylentis Company Information Table 65. Sylentis Business Overview Table 66. Sylentis Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sylentis Oligonucleotide CDMO Product Portfolio Table 68. Sylentis Recent Development Table 69. Ajinomoto Bio-Pharma Company Information Table 70. Ajinomoto Bio-Pharma Business Overview Table 71. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio Table 73. Ajinomoto Bio-Pharma Recent Development Table 74. EUROAPI Company Information Table 75. EUROAPI Business Overview Table 76. EUROAPI Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. EUROAPI Oligonucleotide CDMO Product Portfolio Table 78. EUROAPI Recent Development Table 79. Veliter Company Information Table 80. Veliter Business Overview Table 81. Veliter Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Veliter Oligonucleotide CDMO Product Portfolio Table 83. Veliter Recent Development Table 84. PolyPeptide Group Company Information Table 85. PolyPeptide Group Business Overview Table 86. PolyPeptide Group Oligonucleotide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. PolyPeptide Group Oligonucleotide CDMO Product Portfolio Table 88. PolyPeptide Group Recent Development Table 89. CordenPharma Company Information Table 90. CordenPharma Business Overview Table 91. CordenPharma Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. CordenPharma Oligonucleotide CDMO Product Portfolio Table 93. CordenPharma Recent Development Table 94. Thermofischer Company Information Table 95. Thermofischer Business Overview Table 96. Thermofischer Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Thermofischer Oligonucleotide CDMO Product Portfolio Table 98. Thermofischer Recent Development Table 99. Bio Basic Company Information Table 100. Bio Basic Business Overview Table 101. Bio Basic Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Bio Basic Oligonucleotide CDMO Product Portfolio Table 103. Bio Basic Recent Development Table 104. Genscript Company Information Table 105. Genscript Business Overview Table 106. Genscript Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Genscript Oligonucleotide CDMO Product Portfolio Table 108. Genscript Recent Development Table 109. Cytiva Company Information Table 110. Cytiva Business Overview Table 111. Cytiva Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Cytiva Oligonucleotide CDMO Product Portfolio Table 113. Cytiva Recent Development Table 114. ScinoPharm Company Information Table 115. ScinoPharm Business Overview Table 116. ScinoPharm Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. ScinoPharm Oligonucleotide CDMO Product Portfolio Table 118. ScinoPharm Recent Development Table 119. CBL Company Information Table 120. CBL Business Overview Table 121. CBL Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. CBL Oligonucleotide CDMO Product Portfolio Table 123. CBL Recent Development Table 124. Piramal Pharma Company Information Table 125. Piramal Pharma Business Overview Table 126. Piramal Pharma Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Piramal Pharma Oligonucleotide CDMO Product Portfolio Table 128. Piramal Pharma Recent Development Table 129. CPC Scientific Company Information Table 130. CPC Scientific Business Overview Table 131. CPC Scientific Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. CPC Scientific Oligonucleotide CDMO Product Portfolio Table 133. CPC Scientific Recent Development Table 134. Eurogentec Company Information Table 135. Eurogentec Business Overview Table 136. Eurogentec Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Eurogentec Oligonucleotide CDMO Product Portfolio Table 138. Eurogentec Recent Development Table 139. Cambrex Company Information Table 140. Cambrex Business Overview Table 141. Cambrex Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Cambrex Oligonucleotide CDMO Product Portfolio Table 143. Cambrex Recent Development Table 144. WuXi STA Company Information Table 145. WuXi STA Business Overview Table 146. WuXi STA Oligonucleotide CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 147. WuXi STA Oligonucleotide CDMO Product Portfolio Table 148. WuXi STA Recent Development Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Oligonucleotide CDMO Product Image Figure 2. Global Oligonucleotide CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Oligonucleotide CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. APIs and Intermediates Image Figure 8. FDF Image Figure 9. Global Oligonucleotide CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Oligonucleotide CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Oligonucleotide CDMO Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical and Biotechnology Companies Image Figure 13. Research Institutes Image Figure 14. Others Image Figure 15. Global Oligonucleotide CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oligonucleotide CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oligonucleotide CDMO Sales Value Share by Application (2021-2032) Figure 18. Global Oligonucleotide CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Oligonucleotide CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Oligonucleotide CDMO Sales Value (2021-2032) & (US$ Million) Figure 21. North America Oligonucleotide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Oligonucleotide CDMO Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Oligonucleotide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Oligonucleotide CDMO Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Oligonucleotide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Oligonucleotide CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. South America Oligonucleotide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Oligonucleotide CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Oligonucleotide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Oligonucleotide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • APIs and Intermediates
  • FDF
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
  • Others
Companies covered
  • Agilent
  • ST Pharm
  • Bachem
  • BioSpring
  • Creative Biogene
  • Sylentis
  • Ajinomoto Bio-Pharma
  • EUROAPI
  • Veliter
  • PolyPeptide Group
  • CordenPharma
  • Thermofischer
  • Bio Basic
  • Genscript
  • Cytiva
  • ScinoPharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Eurogentec
  • Cambrex
  • WuXi STA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oligonucleotide CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oligonucleotide CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oligonucleotide CDMO Market Dynamics
  1. 2.1 Oligonucleotide CDMO Industry Trends
  2. 2.2 Oligonucleotide CDMO Industry Drivers
  3. 2.3 Oligonucleotide CDMO Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide CDMO Industry Restraints
3 Oligonucleotide CDMO Market by Company
  1. 3.1 Global Oligonucleotide CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Oligonucleotide CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Oligonucleotide CDMO Company Ranking (2024-2026)
  4. 3.4 Global Oligonucleotide CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Oligonucleotide CDMO Company Product Type and Application
  6. 3.6 Global Oligonucleotide CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oligonucleotide CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oligonucleotide CDMO Market by Type
  1. 4.1 Oligonucleotide CDMO Type Introduction
  2. 4.1.1 APIs and Intermediates
  3. 4.1.2 FDF
  4. 4.2 Global Oligonucleotide CDMO Sales Value by Type
  5. 4.2.1 Global Oligonucleotide CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Oligonucleotide CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Oligonucleotide CDMO Sales Value Share by Type (2021-2032)
5 Oligonucleotide CDMO Market by Application
  1. 5.1 Oligonucleotide CDMO Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology Companies
  3. 5.1.2 Research Institutes
  4. 5.1.3 Others
  5. 5.2 Global Oligonucleotide CDMO Sales Value by Application
  6. 5.2.1 Global Oligonucleotide CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oligonucleotide CDMO Sales Value by Application (2021-2032)
  8. 5.2.3 Global Oligonucleotide CDMO Sales Value Share by Application (2021-2032)
6 Oligonucleotide CDMO Regional Value Analysis
  1. 6.1 Global Oligonucleotide CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oligonucleotide CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oligonucleotide CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oligonucleotide CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oligonucleotide CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Oligonucleotide CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oligonucleotide CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Oligonucleotide CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oligonucleotide CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oligonucleotide CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oligonucleotide CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Oligonucleotide CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oligonucleotide CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oligonucleotide CDMO Sales Value Share by Country, 2025 VS 2032
7 Oligonucleotide CDMO Country-level Value Analysis
  1. 7.1 Global Oligonucleotide CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oligonucleotide CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oligonucleotide CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oligonucleotide CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oligonucleotide CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oligonucleotide CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oligonucleotide CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent
  2. 8.1.1 Agilent Company Information
  3. 8.1.2 Agilent Business Overview
  4. 8.1.3 Agilent Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Oligonucleotide CDMO Product Portfolio
  6. 8.1.5 Agilent Recent Developments
  7. 8.2 ST Pharm
  8. 8.2.1 ST Pharm Company Information
  9. 8.2.2 ST Pharm Business Overview
  10. 8.2.3 ST Pharm Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ST Pharm Oligonucleotide CDMO Product Portfolio
  12. 8.2.5 ST Pharm Recent Developments
  13. 8.3 Bachem
  14. 8.3.1 Bachem Company Information
  15. 8.3.2 Bachem Business Overview
  16. 8.3.3 Bachem Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bachem Oligonucleotide CDMO Product Portfolio
  18. 8.3.5 Bachem Recent Developments
  19. 8.4 BioSpring
  20. 8.4.1 BioSpring Company Information
  21. 8.4.2 BioSpring Business Overview
  22. 8.4.3 BioSpring Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BioSpring Oligonucleotide CDMO Product Portfolio
  24. 8.4.5 BioSpring Recent Developments
  25. 8.5 Creative Biogene
  26. 8.5.1 Creative Biogene Company Information
  27. 8.5.2 Creative Biogene Business Overview
  28. 8.5.3 Creative Biogene Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Creative Biogene Oligonucleotide CDMO Product Portfolio
  30. 8.5.5 Creative Biogene Recent Developments
  31. 8.6 Sylentis
  32. 8.6.1 Sylentis Company Information
  33. 8.6.2 Sylentis Business Overview
  34. 8.6.3 Sylentis Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sylentis Oligonucleotide CDMO Product Portfolio
  36. 8.6.5 Sylentis Recent Developments
  37. 8.7 Ajinomoto Bio-Pharma
  38. 8.7.1 Ajinomoto Bio-Pharma Company Information
  39. 8.7.2 Ajinomoto Bio-Pharma Business Overview
  40. 8.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio
  42. 8.7.5 Ajinomoto Bio-Pharma Recent Developments
  43. 8.8 EUROAPI
  44. 8.8.1 EUROAPI Company Information
  45. 8.8.2 EUROAPI Business Overview
  46. 8.8.3 EUROAPI Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 EUROAPI Oligonucleotide CDMO Product Portfolio
  48. 8.8.5 EUROAPI Recent Developments
  49. 8.9 Veliter
  50. 8.9.1 Veliter Company Information
  51. 8.9.2 Veliter Business Overview
  52. 8.9.3 Veliter Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Veliter Oligonucleotide CDMO Product Portfolio
  54. 8.9.5 Veliter Recent Developments
  55. 8.10 PolyPeptide Group
  56. 8.10.1 PolyPeptide Group Company Information
  57. 8.10.2 PolyPeptide Group Business Overview
  58. 8.10.3 PolyPeptide Group Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PolyPeptide Group Oligonucleotide CDMO Product Portfolio
  60. 8.10.5 PolyPeptide Group Recent Developments
  61. 8.11 CordenPharma
  62. 8.11.1 CordenPharma Company Information
  63. 8.11.2 CordenPharma Business Overview
  64. 8.11.3 CordenPharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CordenPharma Oligonucleotide CDMO Product Portfolio
  66. 8.11.5 CordenPharma Recent Developments
  67. 8.12 Thermofischer
  68. 8.12.1 Thermofischer Company Information
  69. 8.12.2 Thermofischer Business Overview
  70. 8.12.3 Thermofischer Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermofischer Oligonucleotide CDMO Product Portfolio
  72. 8.12.5 Thermofischer Recent Developments
  73. 8.13 Bio Basic
  74. 8.13.1 Bio Basic Company Information
  75. 8.13.2 Bio Basic Business Overview
  76. 8.13.3 Bio Basic Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bio Basic Oligonucleotide CDMO Product Portfolio
  78. 8.13.5 Bio Basic Recent Developments
  79. 8.14 Genscript
  80. 8.14.1 Genscript Company Information
  81. 8.14.2 Genscript Business Overview
  82. 8.14.3 Genscript Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Genscript Oligonucleotide CDMO Product Portfolio
  84. 8.14.5 Genscript Recent Developments
  85. 8.15 Cytiva
  86. 8.15.1 Cytiva Company Information
  87. 8.15.2 Cytiva Business Overview
  88. 8.15.3 Cytiva Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cytiva Oligonucleotide CDMO Product Portfolio
  90. 8.15.5 Cytiva Recent Developments
  91. 8.16 ScinoPharm
  92. 8.16.1 ScinoPharm Company Information
  93. 8.16.2 ScinoPharm Business Overview
  94. 8.16.3 ScinoPharm Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 ScinoPharm Oligonucleotide CDMO Product Portfolio
  96. 8.16.5 ScinoPharm Recent Developments
  97. 8.17 CBL
  98. 8.17.1 CBL Company Information
  99. 8.17.2 CBL Business Overview
  100. 8.17.3 CBL Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CBL Oligonucleotide CDMO Product Portfolio
  102. 8.17.5 CBL Recent Developments
  103. 8.18 Piramal Pharma
  104. 8.18.1 Piramal Pharma Company Information
  105. 8.18.2 Piramal Pharma Business Overview
  106. 8.18.3 Piramal Pharma Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Piramal Pharma Oligonucleotide CDMO Product Portfolio
  108. 8.18.5 Piramal Pharma Recent Developments
  109. 8.19 CPC Scientific
  110. 8.19.1 CPC Scientific Company Information
  111. 8.19.2 CPC Scientific Business Overview
  112. 8.19.3 CPC Scientific Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  113. 8.19.4 CPC Scientific Oligonucleotide CDMO Product Portfolio
  114. 8.19.5 CPC Scientific Recent Developments
  115. 8.20 Eurogentec
  116. 8.20.1 Eurogentec Company Information
  117. 8.20.2 Eurogentec Business Overview
  118. 8.20.3 Eurogentec Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Eurogentec Oligonucleotide CDMO Product Portfolio
  120. 8.20.5 Eurogentec Recent Developments
  121. 8.21 Cambrex
  122. 8.21.1 Cambrex Company Information
  123. 8.21.2 Cambrex Business Overview
  124. 8.21.3 Cambrex Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Cambrex Oligonucleotide CDMO Product Portfolio
  126. 8.21.5 Cambrex Recent Developments
  127. 8.22 WuXi STA
  128. 8.22.1 WuXi STA Company Information
  129. 8.22.2 WuXi STA Business Overview
  130. 8.22.3 WuXi STA Oligonucleotide CDMO Revenue and Gross Margin (2021-2026)
  131. 8.22.4 WuXi STA Oligonucleotide CDMO Product Portfolio
  132. 8.22.5 WuXi STA Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst